Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors

Completed · Phase 1

Conditions studied: Neoplasms

In brief

The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experiences by patients that receive AZD4877 on a weekly basis

Key facts

Study ID

NCT00389389

Run by

AstraZeneca

People needed

75

Starts

2006-09-01

Expected to finish

2008-10-01

Last updated by the study team

2009-05-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Advanced solid tumors for which standard treatment doesn't exist or is no longer effective.
• Relatively good overall health other than your cancer.

You may not qualify if…

• Poor bone marrow function (not producing enough blood cells).
• Serious heart conditions.
• Poor liver or kidney function.

Where it is running

• Research Site — Denver, Colorado, United States
• Research Site — Nashville, Tennessee, United States
• Research Site — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.